Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease

Heart Lung and Circulation

Volumn 14, Issue 2, 2005, Pages 78-84

  Sullivan, David R ^a   West, Malcolm ^b   Jeremy, Richmond ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Brain natriuretic peptide; Cardiovascular disease; Congestive cardiac failure; Myocardium

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN;

AGING; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE MARKER; DYSPNEA; HEALTH CARE COST; HEALTH CARE FACILITY; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RIGHT ATRIUM PRESSURE; HUMAN; IMMUNOASSAY; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; MEDICAL DECISION MAKING; PEPTIDE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 21244478572     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2005.03.002     Document Type: Article

References (78)

1. Inoue K, Naruse K, Yamagami S, Mitani H, Suzuki N, Takei Y. Four functionally distinct C-type natriuretic peptides found in fish reveal evolutionary history of the natriuretic peptide system. Proc Natl Acad Sci USA 2003;100:10079-84.
2. Hira GK, Sarda IR, Wong ST, Pang SC, Flynn TG. Immunoactive iso-ANP/BNP in plasma, tissues and atrial granules of the rat. Regul Pept 1993;44:1-9.
3. Nakao K, Mukoyama M, Hosoda K, Suga S, Ogawa Y, Saito Y, et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991; 69:1500-6.
4. Pedersen EB, Pedersen HB, Jensen KT. Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans. Clin Sci (Colch) 1999;97:201-6.
5. Marumoto K, Hamada M, Aburaya M, Hiwada K. Augmented secretion of atrial and brain natriuretic peptides during dynamic exercise in patients with old myocardial infarction. Jpn Circ J 1995;59:715-24.
6. Gobinet-Georges A, Valli N, Filliatre H, Dubernet MF, Dedeystere O, Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000; 38:519-23.
7. Davidson NC, Struthers AD. Brain natriuretic peptide [review; 91 references]. J Hypertens 1994;12:329-36.
8. Haug C, Metzele A, Kochs M, Hombach V, Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol 1993;16:553-7.
9. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea [see comment]. Lancet 1994;343:440-4.
10. Fruhwald FM, Fahrleitner A, Watzinger N, Fruhwald S, Dobnig H, Schumacher M, et al. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy [see comment]. Eur Heart J 1999;20:1415-23.
11. Yoshibayashi M, Kamiya T, Saito Y, Matsuo H. Increased plasma levels of brain natriuretic peptide in hypertrophic cardiomyopathy. N Engl J Med 1993;329:433-4.
12. Takemura G, Takatsu Y, Doyama K, Itoh H, Saito Y, Koshiji M, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998;31:754-65.
13. Teng YC, Tang XW, Lin QD, Wu YX, Song XL. Relationship between left ventricular diastolic function and plasma brain natriuretic peptide concentration during severe pregnancy-induced hypertension syndrome. Chung Hua I Hsueh Tsa Chih 2003;83:662-5 [Chinese].
14. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, et al. Breathing Not Properly Multinational Study Investigators. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study [see comment]. J Am Coll Cardiol 2003;41: 2010-7.
15. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42:728-35.
16. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
17. Brookes CI, Kemp MW, Hooper J, Oldershaw PJ, Moat NE. Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis 1997;6:608-12.
18. Tharaux PL, Dussaule JC, Hubert-Brierre J, Vahanian A, Acar J, Ardaillou R. Plasma atrial and brain natriuretic peptides in mitral stenosis treated by valvulotomy. Clin Sci (Colch) 1994; 87:671-7.
19. Gerber IL, Stewart RA, Legget ME, West TM, French RL, Sutton TM, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107:1884-90.
20. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003;45:249-54.
21. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. J Cardiol 2001;37:110-1 [in Japanese].
22. Ribeiro AL, dos Reis AM, Barros MV, de Sousa MR, Rocha AL, Perez AA, et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease [see comment]. Lancet 2002; 360:461-2.
23. Kawamura T, Wago M. Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. Cardiol Young 2002;12:153-8.
24. Nakao K. Natriuretic peptide family [review; 20 references]. Nippon Naibunpi Gakkai Zasshi 1992;68:134-42 [in Japanese].
25. Adachi K, Kawai H, Saito M, Naruo T, Kimura C, Mine H, et al. Plasma levels of brain natriuretic peptide as an index for evaluation of cardiac function in female gene carriers of Duchenne muscular dystrophy. Intern Med 1997;36:497-500.
26. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001;37:4-9.
27. Niwa N, Watanabe E, Hamaguchi M, Kodera Y, Miyazaki H, Kodama I, et al. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001;80:460-5.
28. Bordenave L, Georges A, Bareille R, Conrad V, Villars F, Amedee J. Human bone marrow endothelial cells: a new identified source of B-type natriuretic peptide. Peptides 2002;23:935-40.
29. Nagai T, Imamura M, Inukai T, Mori M. Brain natriuretic polypeptide in type 2 NIDDM patients with albuminuria. J Med 2001;32:169-80.
30. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes [see comment]. Circ Res 2003;92:785-92.
31. Ogawa S, Takeuchi K, Ito S. Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab 2003;88:3993-6.
32. McKenna K, Smith D, Moore K, Glen A, Tormey W, Thompson CJ. Brain natriuretic peptide increases urinary albumin and alpha-1 microglobulin excretion in type 1 diabetes mellitus. Diabet Med 2001;18:973-8.
33. Yano Y, Katsuki A, Gabazza EC, Ito K, Fujii M, Furuta M, et al. Plasma brain natriuretic peptide levels in normotensive noninsuhn-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 1999;84:2353-6.
34. Borghi C, Esposti DD, Immordino V, Cassani A, Boschi S, Bovicelli L. Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. Am J Obstet Gynecol 2000;183:140-7.
35. Fleming SM, O'Byrne L, Grimes H, Daly KM, Morrison JJ. Amino-terminal pro-brain natriuretic peptide in normal and hypertensive pregnancy. Hypertens Pregnancy 2001;20:169-75.
36. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-8.
37. Furuhashi N, Kimura H, Nagae H, Yajima A, Kimura C, Saito T. Brain natriuretic peptide and atrial natriuretic peptide levels in normal pregnancy and preeclampsia. Gynecol Obstet Invest 1994; 38:73-7.
38. Mussalo H, Vanninen E, Ikaheimo R, Hartikainen J. NT-proANP and BNP in renovascular and in severe and mild essential hypertension. Kidney Blood Press Res 2003;26:34-41.
39. Almeida P, Azevedo A, Rodrigues R, Dias P, Frioes F, Vazquez B, et al. B-type natriuretic peptide and left ventricular hypertrophy in hypertensive patients [see comment]. Rev Port Cardiol 2003; 22:327-36.
40. Freitag MH, Larson MG, Levy D, Benjamin EJ, Wang TJ, Leip EP, et al. Framingham Heart Study. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension 2003;41:978-83.
41. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction [see comment]. Circulation 2003;107:2786-92.
42. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003;108:2987-92.
43. Mazurek W, Salomon P. The examination of clinical prognostic importance of atrial and brain natriuretic peptide in patients with acute myocardial infarction]. Pol Merkuriusz Lek 2002;12:15-9 [in Polish].
44. Isnard R, Pousset F, Chafirovskaia O, Carayon A, Hulot JS, Thomas D. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J 2003;146:729-35.
45. Ueda R, Yokouchi M, Suzuki T, Otomo E, Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons [see comment]. Am J Med 2003;114:266-70.
46. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. J Am Med Assoc 2002;288: 1252-9.
47. Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van Lente F, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure [see comment]. Circulation 2003;108:2964-6.
48. Cohn JN, Hoke L, Whitwam W, Sommers PA, Taylor AL, Duprez D, et al. Screening for early detection of cardiovascular disease in asymptomatic individuals [see comment]. Am Heart J 2003; 146:679-85.
49. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41:113-20.
50. Hill JA, Hsu K, Pauly DF, Schofield R, Aranda Jr JM. Sustained use of nesiritide to aid in bridging to heart transplant. Clin Cardiol 2003;26:211-4.
51. Sheth T, Parker T, Block A, Hall C, Adam A, Pfeffer MA, et al. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 2002;90:496-500.
52. Bobadilla RV, Oppelt TF, Hirshy TC. Nesiritide treatment of noncardiogenic pulmonary edema. Ann Pharmacother 2003; 37:530-3.
53. Espiner EA, Leikis R, Ferch RD, MacFarlane MR, Bonkowski JA, Frampton CM. The neuro-cardio-endocrine response to acute subarachnoid haemorrhage. Clin Endocrinol (Oxf) 2002;56:629-35.
54. Obi T, Takatsu M, Konishi T, Mizoguchi K, Nishimura Y. Secretion of natriuretic peptides caused by an epileptic attack. Acta Neurol Scand 2002;106:225-8.
55. McLean AS, Huang SJ, Nalos M, Tang B, Stewart DE. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients [see comment]. Crit Care Med 2003; 31:2611-8.
56. Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci (Colch) 2001;101:447-53.
57. Onuoha GN, Nicholls DP, Patterson A, Beringer T. Neuropeptide secretion in exercise. Neuropeptides 1998;32:319-25.
58. Ohba H, Takada H, Musha H, Nagashima J, Mori N, Awaya T, et al. Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men. Am Heart J 2001;141:751-8.
59. Almeida SS, Azevedo A, Castro A, Frioes F, Freitas J, Ferreira A, et al. B-type natriuretic peptide is related to left ventricular mass in hypertensive patients but not in athletes. Cardiology 2002;98:113-5.
60. Wilkins MA, Su XL, Palayew MD, Yamashiro Y, Rolli P, McKenzie JK, et al. The effects of posture change and continuous positive airway pressure on cardiac natriuretic peptides in congestive heart failure. Chest 1995;107:909-15.
61. Thorens JB, Ritz M, Reynard C, Righetti A, Vallotton M, Favre H, et al. Haemodynamic and endocrinological effects of non-invasive mechanical ventilation in respiratory failure. Eur Respir J 1997; 10:2553-9.
62. Tayama K, Takamori S, Mitsuoka M, Hayashi A, Tamura K, Mifune H. Natriuretic peptides after pulmonary resection. Ann Thorac Surg 2002;73:1582-6.
63. Tulevski II, Hirsch A, Sanson BJ, Romkes H, van Der Wall EE, van Veldhuisen DJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 2001;86:1193-6.
64. Ando T, Ogawa K, Yamaki K, Hara M, Takagi K. Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory diseases. Chest 1996;110:462-8.
65. Ishii J, Nomura M, Ito M, Naruse H, Mori Y, Wang JH, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000;301:19-30.
66. Giannitsis E, Katus HA. Still unresolved issues with brain-type natriuretic peptide measurement in the critically ill patient [see comment]. Crit Care Med 2003;31:2703-4.
67. Jones AE, Kline JA. Elevated brain natriuretic peptide in septic patients without heart failure. Ann Emerg Med 2003; 42:714-5.
68. La Villa G, Romanelli RG, Casini Raggi V, Tosti-Guerra C, De Feo ML, Marra F, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 1992;16:156-61.
69. Padillo J, Puente J, Gomez M, Dios F, Naranjo A, Vallejo JA, et al. Improved cardiac function in patients with obstructive jaundice after internal biliary drainage: hemodynamic and hormonal assessment. Ann Surg 2001;234:652-6.
70. Lang CC, Choy AM, Henderson IS, Coutie WJ, Struthers AD. Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clin Sci (Colch) 1992; 82:127-31.
71. Aburaya M, Suzuki E, Minamino N, Kangawa K, Tanaka K, Matsuo H. Concentration and molecular forms of brain natriuretic peptide in rat plasma and spinal cord. Biochem Biophys Res Commun 1991; 177:40-7.
72. Kobusiak-Prokopowicz M, Swidnicka-Szuszkowska B, Mysiak A. Effect of digoxin on atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and cyclic 3′,5′-guanosine monophosphate (cGMP) in patients with chronic congestive heart failure. Pol Arch Med Wewn 2001;105:475-82.
73. Sanderson JE, Chan WW, Hung YT, Chan SK, Shum IO, Raymond K. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995;74:502-7.
74. Hara Y, Hamada M, Shigematsu Y, Suzuki M, Kodama K, Kuwahara T, et al. Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ J 2000; 64:365-9.
75. Takemura K, Yasumura Y, Hirooka K, Hanatani A, Nakatani S, Komamura K, et al. Low-dose amiodarone for patients with advanced heart failure who are intolerant of beta-blockers. Circ J 2002; 66:441-4.
76. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnoea. N Engl J Med 2004;350:647-54.
77. Sparrow N, Adlam D, Cowley A, Hampton JR. The diagnosis of heart failure in general practice: implications for the UK National Service Framework. Eur J Heart Fail 2003;5:349-54.
78. Wang TJ, Larson MG, Levy D, Benjamine EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.